Breaks Categories: Stock Spotlights

FridayMar 17, 2017 12:31 pm

NetworkNewsBreaks – Acura Pharmaceuticals (ACUR) Inks License Agreement with MainPointe Pharmaceuticals for Nexafed® Products

Acura Pharmaceuticals (OTCQB: ACUR) shares are up 5% on news that the company has entered into a License Agreement with MainPointe Pharmaceuticals, LLC in which MainPointe will exclusively market NEXAFED and NEXAFED Sinus in the U.S. and Canada. The NEXAFED brand products, which contain pseudoephedrine, utilize Acura’s IMPEDE® Technology, which disrupts the extraction and conversion of pseudoephedrine into the illicit drug methamphetamine. MainPointe will assume all manufacturing and commercialization activities from Acura. Per the agreement, MainPointe is required to make an upfront cash payment of $2.5 million to Acura, as well as royalty payments of 7.5% based on commercial sales by…

Continue Reading

FridayMar 17, 2017 11:31 am

NetworkNewsBreaks – Singlepoint, Inc. (SING) CEO Discusses Convectium Acquisition in Interview on MoneyTV

Full-service mobile technology and marketing provider Singlepoint, Inc. (OTC: SING) is a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” To view the show, visit www.MoneyTV.net. In this week’s episode, Singlepoint CEO Greg Lambrecht discusses the company’s recently completed acquisition of a stake in Convectium, the creator of the 710Shark and 710Seal system for filling and packaging vape cartridges and disposable vape pens. “The [Convectium] business is doing extremely well, they’ve been in a couple of tradeshows and are selling a lot of…

Continue Reading

ThursdayMar 16, 2017 12:32 pm

NetworkNewsBreaks – Heat Biologics (NASDAQ: HTBX) Receives Grant to Develop Zika Vaccine

Heat Biologics, Inc. (NASDAQ: HTBX) this morning said Natasa Strbo, M.D., D.Sc., research assistant professor of Microbiology and Immunology at the University of Miami Miller School of Medicine, has received a three-year $981,901 grant from the Florida Department of Health 2016-17 Zika Research Grant Initiative to further develop and test the gp96-based Zika vaccine. The vaccine is being developed under a collaboration between the University of Miami and Heat’s wholly owned subsidiary, Zolovax, Inc., which has licensed the patent. The grant is expected to cover the preclinical development of the Zika vaccine, and allow Dr. Strbo to expand her laboratory…

Continue Reading

ThursdayMar 16, 2017 10:25 am

NetworkNewsBreaks – BlackStar Enterprise Group, Inc. (BEGI) CFO Featured in Exclusive Audio Interview with NetworkNewsWire

Merchant banking and finance company BlackStar Enterprise Group, Inc. (OTC: BEGI) was recently featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. The full interview can be heard at http://nnw.fm/begi-interview-march-2017. In the interview, CFO Joseph E. Kurczodyna introduces prospective investors to BlackStar’s operations by describing some of the fundraising challenges that face many private companies. “Right now you've got CEOs raising money, you've got companies that are crowdfunding, and there's a big gap,” he stated.…

Continue Reading

WednesdayMar 15, 2017 4:24 pm

NetworkNewsBreaks – Health Care IT & Big Data Analytics Expanding with the Rise of Value-Based Care Model

At more than $3 trillion per year, U.S. health care spending is a hefty financial burden, demonstrating the need for a more cost- and resource-effective solution. Designed to replace the traditional fee-for-service approach that compensates care providers for the number of services they deliver, the value-based model is emerging as a preferred model that pays providers according to the results of their care. As the health care system shifts toward this approach, there is a growing need for efficient technology platforms and big data analytics that can help curtail rising medical costs and make the overall system more efficient. Leading…

Continue Reading

WednesdayMar 15, 2017 4:23 pm

NetworkNewsBreaks – Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth

As the medical marijuana market continues to grow, so does the number of biotech companies expanding their research into the development of innovative cannabinoid-based pharmaceuticals and delivery systems. It is estimated that the U.S. consumer market for cannabinoid pharmaceuticals will increase exponentially in upcoming years, exceeding $50 billion by 2029, according to Statista. This doesn’t appear to be a lofty forecast, given the prominence this market segment has gained by the sustained efforts and innovations of leading biotech companies such as InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), GW Pharmaceuticals plc (GWPH), Zynerba Pharmaceuticals, Inc. (ZYNE), AXIM® Biotechnologies, Inc. (AXIM) and…

Continue Reading

WednesdayMar 15, 2017 4:21 pm

NetworkNewsBreaks – “No-Touch” Approach Reduces Risk as Public Companies Tap Explosive Growth of Cannabis Industry

The marijuana industry is the new investing frontier. As a result of last November’s elections, eight states and the District of Columbia now allow the recreational use of marijuana, while another 28 states permit its use for medicinal purposes. In what has been touted as the fastest-growing industry in the U.S., investment opportunities in the cannabis space appear boundless. Companies like Singlepoint, Inc. (SING) (SING Profile), American Cannabis Company Inc. (AMMJ), General Cannabis Corp. (CANN), The Scotts Miracle-Gro Company (SMG) and Terra Tech Corp. (TRTC) are all employing a “no-touch” approach to their cannabis business models. By creating business models…

Continue Reading

WednesdayMar 15, 2017 12:08 pm

NetworkNewsBreaks – UGE International Ltd. (UGEIF) Shares Spike on New Contract for NYC’s First Community Solar Project

Shares of UGE International (OTCQB: UGEIF) are ticking higher after the clean energy company said it has secured a contract to develop and build New York City's first community solar project at a multi-tenant commercial facility in Brooklyn. Located in a neighborhood between Park Slope and Boerum Hill, the project will have a rated peak capacity of approximately 100 kilowatts, providing clean energy to be net metered and sold to residential off-takers at rates lower than their utility payments. The project is the first of several under development by UGE and Gotham Community Solar LLC, a company owned by Peter…

Continue Reading

WednesdayMar 15, 2017 11:40 am

NetworkNewsBreaks – Cesca Therapeutics (NASDAQ: KOOL) Spike on Encouraging Data for Chronic Non-Healing Ulcers Treatment

Shares of Cesca Therapeutics’ (NASDAQ: KOOL) are up 12% mid-morning on promising data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers. The study, entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series,” was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute. Results from the 24 patient study were published in the peer-reviewed Journal of Biomedical Science. During the study, 24 patients with one wound or ulcer were treated with a single dose of PRP injections around the…

Continue Reading

WednesdayMar 15, 2017 11:38 am

NetworkNewsBreaks – Catalyst Pharmaceuticals (NASDAQ: CPRX) Shares Rally on Positive Data from Investigator-Sponsored Trial of Firdapse®

Shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) are up more than 40% this morning following the company’s release of positive top-line results from the investigator-sponsored trial evaluating Firdapse® as a treatment for myasthenia gravis (MG) patients with anti-MuSK antibodies (MuSK-MG). MuSK-MG is an extremely rare form of MG with no FDA approved therapies currently available. Both of the co-primary efficacy endpoints of change from baseline (CFB) in total quantitative myasthenia gravis score and CFB in total myasthenia gravis activities of daily living score were statistically and clinically significant in this trial. Several secondary efficacy measures also achieved statistical significance, and the…

Continue Reading